5 November 2021 - Biocom California, the association representing the California life science industry, issued the following statement regarding the drug pricing portion in the “Build Back Better” legislation. 

The statement can be attributed to Joe Panetta, Biocom California’s president and CEO:

“On behalf of our more than 1,500 members across California, I am deeply concerned that the U.S. House of Representatives has decided to move forward with a drug pricing and access proposal that endorses price setting, undermines intellectual property protections, and would place an unfair burden on innovative life science companies, despite repeated warnings by the biomedical research community that such policies would hurt innovation and reduce patients’ access to life-saving products.

Read Biocom California press release